| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade | Science | 2017 | 3.3K |
| First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2017 | 1.5K |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | New England Journal of Medicine | 2017 | 1.1K |
| Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial | JAMA - Journal of the American Medical Association | 2017 | 434 |
| Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer | JAMA Oncology | 2017 | 335 |
| NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 319 |
| The Broad Spectrum of Human Natural Killer Cell Diversity | Immunity | 2017 | 302 |
| NCCN Guidelines Insights: Breast Cancer, Version 1.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 249 |
| NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 207 |
| NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 197 |
| NCCN Guidelines Insights: Bone Cancer, Version 2.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 139 |
| Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer | Journal of the National Cancer Institute | 2017 | 138 |
| tsRNA signatures in cancer | Proceedings of the National Academy of Sciences of the United States of America | 2017 | 131 |
| Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial | Lancet Oncology, The | 2017 | 106 |
| NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 106 |
| Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma | Annals of Oncology | 2017 | 101 |
| NCCN Guidelines Insights: Antiemesis, Version 2.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 92 |
| In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice | Circulation Research | 2017 | 86 |
| RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21 | Molecular Therapy | 2017 | 83 |
| NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 81 |
| EXTH-83. TARGETING DNA REPAIR AND SURVIVAL PATHWAYS THROUGH HEAT SHOCK PROTEIN INHIBITION USING AT13387 TO SENSITIZE GLIOMA TO CHEMORADIATION THERAPY | Neuro-Oncology | 2017 | 78 |
| ETHNIC DISPARITIES IN CANCER INCIDENCE AND SURVIVAL AMONG THE OLDEST OLD IN THE UNITED STATES | Innovation in Aging | 2017 | 78 |
| EXTH-84. TARGETING THE SALVAGE PATHWAY OF NAD+ GENERATION IN GLIOMAS BY KPT-9274, A NOVEL DUAL INHIBITOR OF PAK4 AND NAMPT | Neuro-Oncology | 2017 | 78 |
| Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review | Surgery | 2017 | 76 |
| MicroRNAs in melanoma development and resistance to target therapy | Oncotarget | 2017 | 74 |
